ASAtsuyuki Saisyo

Atsuyuki Saisyo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Atsuyuki Saisyo has a total of 38 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Treatment of Inflammatory Bowel Disease with Biologics in Japan: A Single-Center, Retrospective Pharmacoeconomic Study

    by Atsuyuki Saisyo, Shinichi Hashimoto, Haku Ishida, Koichi Kashibe, Tomoyuki Oka, Yasushi Hirano, Miwako Takasago, Yutaka Uchida, Naoto Okada, Taro Takami, et al.

    Biologics are essential for treating inflammatory bowel disease (IBD); however, only a few studies have validated cost-effective treatment options and patient factors for biologic use using real-world data from Japanese patients with IBD. Here, we aimed to provide pharmacoeconomic evidence to support clinical decisions for IBD treatment using biologics. We assessed 183 cases (127 patients) of IBD treated with biologics between November 2004 and September 2021. Data on patient background, treatment other than biologics, treatment-related medical costs, and effectiveness index (ratio of the C-reactive protein-negative period to drug survival time) were analyzed using univariate and multivariate logistic regression analyses. Drug survival was determined using Kaplan–Meier survival curve analysis. The outcomes were to validate a novel assessment index and elucidate the following aspects using this index: the effectiveness–cost relationship of long-term biologic use in IBD and cost-effectiveness-associated patient factors. Body mass index ≥25 kg/m2 and duration of hypoalbuminemia during drug survival correlated significantly with the therapeutic effectiveness of biologics. There were no significant differences in surgical, granulocyte apheresis, or adverse-event costs per drug survival time. Biologic costs were significantly higher in the group showing lower effectiveness than in the group showing higher effectiveness. These findings hold major pharmacoeconomic implications for not only improving therapeutic outcomes through the amelioration of low albumin levels and obesity but also potentially reducing healthcare expenditure related to the use of biotherapeutics. To our knowledge, this is the first pharmacoeconomic study based on real-world data from Japanese patients with IBD receiving long-term biologic therapy.

  • Disproportionality Analysis on Hypothyroidism With Roxadustat Using the Japanese Adverse Drug Event Database

    by Yasunobu Kouki, Naoto Okada, Kosuke Saga, Masakazu Ozaki, Atsuyuki Saisyo, Takashi Kitahara

    Hypoxia‐inducible factor prolyl‐hydroxylase inhibitor (HIF‐PHI) is a novel agent for the treatment of renal anemia. HIF‐PHI increases endogenous erythropoietin production by inhibiting the degradation of an erythropoietin transcription factor. Although beneficial effects are expected from HIF‐PHI, its novel mechanism raises concerns regarding the risk of potential adverse events. The cases of hypothyroidism, which had not been reported in clinical trials, were reported after the administration of roxadustat in a real‐world setting. However, the effects of HIF‐PHIs on thyroid function have not yet been fully evaluated. This study aimed to assess the clinical impact of HIF‐PHIs on thyroid function using the Japanese Adverse Drug Event Report database, a spontaneous reporting system in Japan, because HIF‐PHIs were made available in Japan before they were available in other countries. Although a disproportionality signal for hypothyroidism was detected with roxadustat (reporting odds ratio [ROR]:22.1, 95% confidence interval [CI]:18.3‐26.7, no signals were detected with another HIF‐PHI, daprodustat (ROR:1.3, 95%CI:0.3‐5.4), and epoetin beta pegol (ROR:1.2, 95%CI:0.5‐2.7). Signals of hypothyroidism due to roxadustat were also detected regardless of age or sex. Approximately 50% of hypothyroidism cases were reported within 50 days of starting roxadustat use. These results indicate that roxadustat use may be related to the development of hypothyroidism. The need for monitoring of thyroid function should be alerted during roxadustat administration regardless of age or sex.


  • A low prognostic nutritional index is associated with increased remote infections within 30 days of colorectal surgery: A retrospective cohort study

    by Tomoyuki Oka, Kyoji Kouda, Naoto Okada, Atsuyuki Saisyo, Kouichi Kashibe, Yasushi Hirano, Sakurao Hiraki, Hirofumi Yamasaki, Haku Ishida, Takashi Kitahara


  • Pharmacoeconomic study of biologics for psoriasis treatment based on real‐world drug survival

    by Atsuyuki Saisyo, Michiya Yamaguchi, Koichi Kashibe, Haku Ishida, Yasushi Hirano, Tomoyuki Oka, Miho Tamura, Miwako Takasago, Yutaka Uchida, Kyoji Kouda, et al.

    The efficacy of biologics in psoriasis treatment is clinically proven; however, biologics are expensive. In this study, we assessed the real-world cost-effectiveness of biologics for psoriasis treatment by evaluating the relationship between biologic drug survival (DS) and total medical-treatment costs from a pharmacoeconomic viewpoint. Furthermore, the effects of patient factors on cost-effectiveness were investigated. We retrospectively reviewed the medical records of 135 patients who received either a tumor necrosis factor-alpha (TNF-α) monoclonal antibody (TNF-mab), interleukin (IL)-17 mab, or IL23p19-mab for psoriasis from January 2010 to June 2020 at Yamaguchi University Hospital. We compared the monthly medical-treatment costs according to biologic classification and found that costs of medical services, tests, and external preparations required for the treatment process were significantly higher in the TNF-mab group than in the other groups, and the total medical costs associated with TNF-mab treatment were significantly higher than those of IL17-mab treatment. The total monthly cost of medical care was lower in the long-term DS group than in the short-term group. The number of prescriptions for external preparations, comprising Vitamin.D3 and corticosteroid, was significantly higher in the long-term DS group than in the short-term group; in the TNF-mab group, the proportion of patients without smoking habits was significantly higher in the long-term group as well. Our study indicated that when costly biologics are used for psoriasis treatment, the maintenance of long-term DS and appropriate patient guidance may improve the quality of medical care, thus allowing cost-effective medical care.


  • Open Access

    Evaluation of a Hypnotics Usage Flowchart for Standardizing Insomnia Indicators in Order to Prevent Falls

    by Miwako Takasago, Atsuyuki Saisyo, Kazuki Wakabayashi, Mari Akiyama, Yuko Fujii, Tomoe Seki, Kyoji Kouda, Kazuto Matsunaga, Takashi Kitahara

    We developed a flowchart for standardizing insomnia treatment to prevent falls associated with hypnotic drug dosing in Yamaguchi University Hospital, and implemented it from April 2019. The first recommended drug was suvorexant, followed by eszopiclone. In November 2019, we conducted a questionnaire survey involving doctors and nurses regarding the effectiveness and convenience of the flowchart. Eighty-one percent of the participants responded positively. We also investigated the incidence of falls within 24 h after dosing hypnotics. The fall rate before and after the introduction of the flowchart was no significant difference as determined by propensity score matching of the patient background. However, the fall rate for patients who received the recommended drugs was 3.1% and that for patients who received the deprecated drugs was 5.7%. Therefore, the fall rate of patients receiving the recommended drugs was significantly lower than that of patients receiving the deprecated drugs. The introduction of this flowchart may thus help prevent patient falls.

  • Standardization of Hypnotic Agents for Prevention of Falls: A Pharmacoeconomic Study

    by Atsuyuki Saisyo, Miwako Takasago, Kazuki Wakabayashi, Mari Akiyama, Kyoji Kouda, Akihisa Takasaki, Kazuto Matsunaga, Haku Ishida, Takashi Kitahara

    To reduce the number of falls caused by hypnotic agents, the standardization of insomnia treatment was carried out at Yamaguchi University Hospital from April 2019. There were concerns that medical costs would increase due to the selected medicines―suvorexant and eszopiclone―being more expensive than conventional benzodiazepines. In this study, the standardization of insomnia treatment was evaluated by pharmacoeconomics. The costs of the hypnotic agents was considered, as was the cost of examination/treatment following falls. Effectiveness was evaluated as the incidence of falls within 24 hours of taking hypnotic agents. This analysis took the public healthcare payer's perspective. Propensity score matching based on patient background, showed that, per hospitalization the medicine costs of the recommended group increased by 1,020 yen, however, the examination/treatment costs following falls decreased by 487 yen when compared with the non-recommended group. Overall, the recommended group incurred costs of 533 yen more per hospitalization for patients prescribed hypnotic agents compared to the non-recommended group, but the incidence of falls for the recommended group was significantly lower than that in the non-recommended group (1.9% vs. 6.3%; p<0.01). These results suggest that in order to prevent the incidence of falls by 1 case, it is necessary to increase costs by 12,086 yen which is the subthreshold cost for switching to the recommended medicine as standardization. The selection of recommended medicines may be a cost-effectiveness option compared with non-recommended medicines.